Gilead Sciences, Inc. income statement & cash flow
In the fiscal year ended Dec 31, 2025, Gilead Sciences, Inc. reported net income of $8.51B on revenue of $29.44B. Operating cash flow was $10.02B and capital expenditures were $563.00M, leaving $9.46B of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| Operating income | $17.63B | $14.12B | $8.20B | $4.29B | $4.07B | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B |
| Net income | $13.50B | $4.63B | $5.46B | $5.39B | $123.00M | $6.22B | $4.59B | $5.67B | $480.00M | $8.51B |
| Diluted EPS | $9.94 | $3.51 | $4.17 | $4.22 | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Operating cash flow | $17.05B | $11.90B | $8.40B | $9.14B | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B |
| Capital expenditures | — | — | $924.00M | $825.00M | $650.00M | $579.00M | $728.00M | $585.00M | $523.00M | $563.00M |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | — | 34.0% | 28.9% |
| Dec 2024 | — | 5.8% | 1.7% |
| Dec 2023 | — | 28.0% | 20.9% |
| Dec 2022 | — | 26.9% | 16.8% |
| Dec 2021 | — | 36.3% | 22.8% |
Source: SEC EDGAR XBRL company facts for CIK 882095 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.